Naibec Presents Research on 'Liver Fibrosis' Treatment at the World's Most Prestigious Keystone Symposia

[Asia Economy Reporter Hyunseok Yoo] Naivek, a peptide fusion bio-specialized company, has been selected for the globally renowned academic conference ‘Keystone Symposia’ and will present research results on non-alcoholic steatohepatitis and liver fibrosis. Keystone Symposia is an international conference with the highest authority in the fields of cancer new drugs, genetics, and molecular biology.

Naivek announced on the 19th that it will present research results on the non-alcoholic steatohepatitis treatment ‘NIPEP-NASH’ and fibrosis treatment ‘NIPEP-PF’ in the session ‘Fatty Liver Disease and Multi-System Complications’ from the 22nd to the 24th.

‘NAFLD’, a disease causing fat accumulation in the liver due to unbalanced diet or lack of exercise in people without obesity or drinking history, is rapidly increasing worldwide, but there is currently no approved treatment. If NAFLD worsens, it is likely to progress to ‘NASH’, non-alcoholic steatohepatitis, which significantly increases the risk of progressive fibrosis and hepatocellular carcinoma (HCC). Since there are no approved drugs for ‘NASH’ either, global biotech and pharmaceutical companies are focusing on discovering early-stage candidate substances. This means that if successful in developing treatments, the market potential is substantial due to the large number of patients.

At this Keystone Symposia, invited experts will explore the genetic factors of ‘AFLD’ and consider its correlation with NASH and liver cirrhosis. Discussions will include not only the mechanisms of various substances currently under development aimed at discovering new drugs related to NASH but also the scientific validity underlying each mechanism. Presenting at Keystone Symposia itself is regarded as having undergone a scientific verification process.

The peptide therapeutics developed by Naivek effectively inhibit ‘biomarkers’ that uniquely increase in NASH and NAFLD, reducing liver tissue inflammation and fat accumulation as well as eliminating fibrosis.

A Naivek official stated, “When liver tissue is damaged, normal liver cells transform into fibroblast forms, and these degenerated fibroblasts overproduce ‘fibrous proteins’, causing liver tissue fibrosis and cirrhosis. NIPEP-NASH reduces the transition mechanism that converts normal cells into fibroblasts, effectively reprogramming the fibrotic cells back into normal cells.”

He added, “The global biotech company currently collaborating with us conducted experiments based on animal models induced by ‘methionine’-deficient diets and ‘STAM’ animal models that induce fatty liver, demonstrating that Naivek’s therapeutics suppress liver fibrosis and inflammation. This shows that the treatment is more effective for NASH caused by complex factors.” He continued, “At this Keystone Symposia, we plan to introduce the mechanism of NIPEP-NASH treatment, present animal efficacy study results, and share current progress. Naivek also plans to conduct safety studies on NIPEP-NASH.”